Oscar, I disagree with your second paragraph regarding "dilutingh their resources". If Newjos post is accurate they are concentrating by proving their technology across 42 differant drugs. They probably won;t take any drugs to market on the own.
Their strategy is to license or co-develop all their products. The technology has such a broad range of applications it would be well beyond their ability to maximise its potential alone.
PoS.
- Forums
- ASX - By Stock
- AVE
- poh negatives
poh negatives, page-4
Featured News
Add AVE (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.923M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
35 | 43869108 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 44263580 | 22 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
35 | 43869108 | 0.002 |
16 | 22966742 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 44170247 | 21 |
0.004 | 34681763 | 17 |
0.005 | 16900219 | 10 |
0.006 | 9723435 | 9 |
0.007 | 13229103 | 6 |
Last trade - 16.12pm 04/10/2024 (20 minute delay) ? |
Featured News
AVE (ASX) Chart |
Day chart unavailable